Addendum
Cariprazine (schizophrenia) - Addendum to Commission A18-25
Report documents
-
Addendum
Cariprazine (schizophrenia) - Addendum to Commission A18-25
Dossier assessment
Indication:
Adults with schizophrenia, outcome "akathisia"
Result of dossier assessment:
Long-term treatment: In patients with mostly negative symptoms hint of a non-quantifiable added benefit. Remaining patients as well as acute treatment: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2018-10-04 A G-BA decision was published.
Project details
- Project no.
- A18-50
- Commission
- Commission awarded on 22.08.2018 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Mental and emotional wellbeing
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Cariprazine (schizophrenia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed